Severe hemolytic anemia and skin reaction in a patient treated with imatinib.
De Arriba
J-J
JJ
Nerín
C
C
García
E
E
Gómez-Aldaraví
L
L
Vila
B
B
D000310:Adrenal Gland Neoplasms / Q000188:drug therapy / Q000556:secondary; D000743:Anemia, Hemolytic / Q000139:chemically induced* / Q000503:physiopathology; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001549:Benzamides; D005076:Exanthema / Q000139:chemically induced* / Q000503:physiopathology; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors; D013160:Splenic Neoplasms / Q000188:drug therapy / Q000556:secondary; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate